Aptevo Therapeutics (APVO) FCF Margin (2015 - 2022)
Aptevo Therapeutics (APVO) posted FCF Margin of 164.32% for Q1 2022, down 50.64% sequentially from 109.09% in Q4 2021, and up 15352.0% YoY from N/an in Q1 2021.
Aptevo Therapeutics (APVO) FCF Margin (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported FCF Margin for 8 years, with the latest figure at 164.32% in Q1 2022.
- Quarterly FCF Margin rose 15352.0% year-over-year to 164.32% in Q1 2022, while the trailing twelve-month figure through Dec 2022 was 675.21% (down 49304.0% YoY) and the FY2022 annual result came in at 676.01%, down 49384.0% from the prior year.
- FCF Margin retreated to 164.32% in Q1 2022 per APVO's latest filing, from 109.09% in the prior quarter.
- Over five years, FCF Margin peaked at 56.47% in Q4 2019 and troughed at 979.49% in Q2 2020.
- A 5-year average of 282.67% and a median of 215.91% in 2019 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2020 and 2021: FCF Margin plunged 76358 bps in 2020, then jumped 80444 bps in 2021.
- Over 5 years, FCF Margin stood at 269.46% in 2018, then surged by 79 bps to 56.47% in 2019, then tumbled by 357 bps to 258.03% in 2020, then surged by 58 bps to 109.09% in 2021, then slumped by 51 bps to 164.32% in 2022.
- According to Business Quant data, FCF Margin over the past three periods registered 164.32%, 109.09%, and 169.74% for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 70.82% |
| 10 | Aptevo Therapeutics | 3.19 Mn | -6.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -164.32% |
| Dec 31, 2021 | -109.09% |
| Sep 30, 2021 | -169.74% |
| Jun 30, 2021 | -175.05% |
| Mar 31, 2021 | -317.84% |
| Dec 31, 2020 | -258.03% |
| Sep 30, 2020 | -504.92% |
| Jun 30, 2020 | -979.49% |
| Dec 31, 2019 | -56.47% |
| Sep 30, 2019 | -83.76% |
| Jun 30, 2019 | -215.91% |
| Mar 31, 2019 | -199.33% |
| Sep 30, 2018 | -269.46% |
| Jun 30, 2018 | -307.89% |
| Mar 31, 2018 | -428.67% |
| Sep 30, 2017 | -28.37% |
| Jun 30, 2017 | -359.76% |
| Mar 31, 2017 | -598.55% |
| Dec 31, 2016 | -82.61% |
| Sep 30, 2016 | -3.13% |